ATE460938T1 - Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion - Google Patents

Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion

Info

Publication number: ATE460938T1
Authority: AT; Austria
Prior art keywords: treatment; sexual dysfunction; dopamine agonists; morpholine derivatives; morpholine
Prior art date: 2002-12-10

Application number

AT03812639T

Other languages

English (en)

Inventor

Charlotte ALLERTON

Andrew Baxter

Andrew Cook

David Hepworth

Stephen Wong

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-10

Filing date

2003-12-02

Publication date

2010-04-15

2002-12-10 Priority claimed from GB0228787A external-priority patent/GB0228787D0/en

2003-04-11 Priority claimed from GB0308460A external-priority patent/GB0308460D0/en

2003-06-12 Priority claimed from GB0313606A external-priority patent/GB0313606D0/en

2003-12-02 Application filed by Pfizer filed Critical Pfizer

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE460938T1 publication Critical patent/ATE460938T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Dermatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

AT03812639T 2002-12-10 2003-12-02 Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion ATE460938T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0228787A GB0228787D0 (en)	2002-12-10	2002-12-10	Morpholine dopamine agonists
GB0308460A GB0308460D0 (en)	2003-04-11	2003-04-11	Morpholine dopamine agonists
GB0313606A GB0313606D0 (en)	2003-06-12	2003-06-12	Morpholine dopamine agonists
PCT/IB2003/005683 WO2004052372A1 (en)	2002-12-10	2003-12-02	Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Publications (1)

Publication Number	Publication Date
ATE460938T1 true ATE460938T1 (de)	2010-04-15

Family

ID=32512061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03812639T ATE460938T1 (de)	2002-12-10	2003-12-02	Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion

Country Status (36)

Country	Link
EP (1)	EP1572214B1 (de)
JP (3)	JP3889775B2 (de)
KR (1)	KR100796102B1 (de)
AP (1)	AP2005003325A0 (de)
AR (1)	AR042339A1 (de)
AT (1)	ATE460938T1 (de)
AU (1)	AU2003302878B2 (de)
CA (1)	CA2508262C (de)
CO (1)	CO5700781A2 (de)
CR (1)	CR7869A (de)
CY (1)	CY1110130T1 (de)
DE (1)	DE60331769D1 (de)
DK (1)	DK1572214T3 (de)
EA (1)	EA009589B1 (de)
EC (1)	ECSP055850A (de)
ES (1)	ES2339767T3 (de)
GE (1)	GEP20074272B (de)
HN (1)	HN2003000401A (de)
HR (1)	HRP20050523A2 (de)
IS (1)	IS7843A (de)
MA (1)	MA27605A1 (de)
MX (1)	MXPA05006151A (de)
MY (1)	MY144338A (de)
NL (1)	NL1024983C2 (de)
NO (1)	NO330143B1 (de)
NZ (1)	NZ540505A (de)
OA (1)	OA13014A (de)
PA (1)	PA8591601A1 (de)
PE (1)	PE20040906A1 (de)
PL (1)	PL377480A1 (de)
PT (1)	PT1572214E (de)
RS (1)	RS51442B (de)
SI (1)	SI1572214T1 (de)
TW (1)	TW200423944A (de)
UY (1)	UY28117A1 (de)
WO (1)	WO2004052372A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4093588B2 (ja) *	2004-05-26	2008-06-04	ファイザー・インク	新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
BRPI0511571A (pt) *	2004-05-27	2008-01-02	Pfizer	derivados de aminopiridina como agonistas de dopamina d3 seletivos
GB0502509D0 (en)	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) *	2007-01-15	2007-02-21	Pfizer Ltd	Morpholine dopamine agonists for the treatment of pain
EP2571859B1 (de)	2010-05-21	2015-07-22	Research Triangle Institute	1-phenylmorpholine-derivative als hydroxybupropion analogen bei der behandlung von drogenabhängigkeit
WO2011146850A1 (en) *	2010-05-21	2011-11-24	Research Triangle Institute	Phenylmorpholines and analogues thereof
PL3080284T3 (pl)	2013-12-11	2018-05-30	F.Hoffmann-La Roche Ag	Sposób wytwarzania chiralnej 2-(4-aminofenylo)morfoliny
GB2543296A (en) *	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
EP3953350A1 (de)	2019-04-12	2022-02-16	The United States of America, as Represented by The Department of Health and Human Services	D3-rezeptor-agonist-verbindungen, verfahren zur herstellung, zwischenprodukte davon und verwendungsverfahren dafür
EP3725768A1 (de) *	2019-04-17	2020-10-21	Newron Pharmaceuticals S.p.A.	Verfahren zur herstellung von substituierten 2-[2-(phenyl)ethylamino]alkanamid-derivaten
CN118684636B (zh) *	2024-05-31	2025-03-11	上海优合贝德医药科技有限公司	一种4-吗啉-1-苯基巯基-2-丁酮的合成工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB851311A (en) *	1958-04-02	1960-10-12	Geigy Ag J R	Morpholine compounds and their production
GB9108629D0 (en) *	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction

2003
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active Expired - Fee Related
- 2003-12-02 EP EP03812639A patent/EP1572214B1/de not_active Expired - Lifetime
- 2003-12-02 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/sr unknown
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en not_active Ceased
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
2006
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown

Also Published As

Publication number	Publication date
DE60331769D1 (de)	2010-04-29
MY144338A (en)	2011-08-29
PE20040906A1 (es)	2005-01-24
NZ540505A (en)	2007-02-23
MA27605A1 (fr)	2005-11-01
JP2006232857A (ja)	2006-09-07
AU2003302878B2 (en)	2009-04-23
ES2339767T3 (es)	2010-05-25
WO2004052372A1 (en)	2004-06-24
AU2003302878A1 (en)	2004-06-30
JP4624341B2 (ja)	2011-02-02
UY28117A1 (es)	2004-07-30
NO20052557L (no)	2005-09-06
PT1572214E (pt)	2010-05-06
EP1572214A1 (de)	2005-09-14
HRP20050523A2 (en)	2005-08-31
CA2508262C (en)	2009-12-01
PL377480A1 (pl)	2006-02-06
KR20050094813A (ko)	2005-09-28
MXPA05006151A (es)	2005-08-26
GEP20074272B (en)	2007-12-25
CA2508262A1 (en)	2004-06-24
PA8591601A1 (es)	2004-12-16
NL1024983A1 (nl)	2004-06-11
HN2003000401A (es)	2004-11-23
JP2007084575A (ja)	2007-04-05
AP2005003325A0 (en)	2005-06-30
AR042339A1 (es)	2005-06-15
SI1572214T1 (sl)	2010-07-30
KR100796102B1 (ko)	2008-01-21
RS51442B (sr)	2011-04-30
EA009589B1 (ru)	2008-02-28
TW200423944A (en)	2004-11-16
CR7869A (es)	2005-07-08
EA200500801A1 (ru)	2005-12-29
IS7843A (is)	2005-05-12
JP3889775B2 (ja)	2007-03-07
JP2006511599A (ja)	2006-04-06
NL1024983C2 (nl)	2005-02-01
CO5700781A2 (es)	2006-11-30
NO20052557D0 (no)	2005-05-26
CY1110130T1 (el)	2015-01-14
NO330143B1 (no)	2011-02-21
DK1572214T3 (da)	2010-06-07
HK1081850A1 (zh)	2006-05-26
EP1572214B1 (de)	2010-03-17
RS20050445A (sr)	2007-04-10
JP3920908B2 (ja)	2007-05-30
ECSP055850A (es)	2005-09-20
OA13014A (en)	2006-11-10

Publication	Publication Date	Title
LTPA2016037I1 (lt)	2017-01-10	Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
ATE410430T1 (de)	2008-10-15	2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602004012154D1 (de)	2008-04-10	Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
EA200600203A1 (ru)	2006-08-25	Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
ATE478049T1 (de)	2010-09-15	Phosphodiesterase-4-inhibitoren, einschliesslich n-substituierter diarylaminanaloga
EA200501928A1 (ru)	2006-12-29	Пирролодигидроизохинолины как ингибиторы pde10
DE602005026984D1 (de)	2011-04-28	Chinolin-derivate zur behandlung von latenter tuberkulose
EA200300527A1 (ru)	2003-08-28	Новые способы лечения синдрома "усталых ног"
CY1110130T1 (el)	2015-01-14	Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
DK1694122T3 (da)	2007-12-03	N-arylhydrazonderivater til fröbehandling
ATE486597T1 (de)	2010-11-15	3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602005012481D1 (de)	2009-03-12	2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
DE60328603D1 (de)	2009-09-10	Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
CL2003002293A1 (es)	2005-01-14	Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
UY28344A1 (es)	2005-01-31	Nuevos compuestos
DE602004006118D1 (de)	2007-06-06	2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE460166T1 (de)	2010-03-15	Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE60127712D1 (de)	2007-05-16	Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DE602006005640D1 (de)	2009-04-23	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
CL2004001507A1 (es)	2005-05-27	Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.
CR8009A (es)	2008-09-10	Compuestos benzo[1,2,5] tiadiazoles
DE602006002608D1 (de)	2008-10-16	4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE602004019698D1 (de)	2009-04-09	Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
DE602004003252D1 (de)	2006-12-28	Verwendung von 2h-ä1,3ü-oxazinoä3,2-aüindol-derivaten zur behandlung von neuropathischem schmerz

Legal Events

Date	Code	Title	Description
2010-09-15	UEP	Publication of translation of european patent specification	Ref document number: 1572214 Country of ref document: EP

Date

Code

Title

Description

2010-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1572214

Country of ref document: EP